EMD-47385

Single-particle
2.68 Å
EMD-47385
3D View Gallery
Deposition: 21/10/2024
Map released: 30/10/2024
Last modified: 25/06/2025
Overview 3D View Sample Experiment Validation Additional data Links
Overview 3D View Sample Experiment Validation Additional data Links

EMD-47385

Archive Files (Depositor)

Primary 3D volume (map.gz) Half-map 1 Half-map 2 (map.gz) Experimental metadata (xml) Experimental metadata (cif.gz)

Validation (wwPDB)

Map-only validation report (pdf.gz) Map-9e18 summary report (pdf.gz) Map-9e18 FULL report (pdf.gz)

EMDB Annotations

EMICSS entry mapping (xml)

Structure of RyR1 in the primed state in the presence of pentoxifylline

EMD-47385

Single-particle
2.68 Å
EMD-47385
3D View Gallery
Deposition: 21/10/2024
Map released: 30/10/2024
Last modified: 25/06/2025
Overview 3D View Sample Experiment Validation Additional data Links
Sample Organism: Oryctolagus cuniculus
Sample: Complex of RyR1 and Calstabin-1
Fitted models: 9e18

Deposition Authors: Miotto MC , Marks AR
Targeting ryanodine receptors with allopurinol and xanthine derivatives for the treatment of cardiac and musculoskeletal weakness disorders.
Miotto MC , Luna-Figueroa E, Tchagou C, Bahlouli L, Reiken S , Dridi H, Liu Y , Weninger G , Marks AR
(2025) PNAS , 122 , e2422082122 - e2422082122
PUBMED: 40512792
DOI: doi:10.1073/pnas.2422082122
ISSN: 1091-6490
ASTM: PNASA6
Grant Support: